Advanced High-Content-Screening Applications of Clonogenicity in Cancer.

SLAS Discov

The Department of Pharmaceutical Sciences, The University of Colorado Anschutz Medical Campus, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA.

Published: August 2020

AI Article Synopsis

  • The clonogenic assay, established in 1956, evaluates cancer cell survival and has evolved to assess cancer stem cell (CSC) properties, highlighting their ability to form colonies and resist treatment.
  • Despite the availability of automated systems, integrating clonogenic assays into high-content screening (HCS) workflows has been challenging.
  • The proposed HCS method uses an Opera Phenix system to quantify colony characteristics in both 2D and 3D cultures, potentially enhancing cancer research and targeted therapy development.

Article Abstract

Since its first report in 1956 by Puck and Marcus, the clonogenic assay has not been completely adapted into high-content-screening (HCS) workflows despite the numerous automated systems available. Initially, clonogenic assays were used to observe the effects of radiation on cell survival, particularly with cancer cells. The clonogenic assay has since been well characterized as a measure of cancer stem cell (CSC) stemness, demonstrating that a single CSC can generate clonogenic colonies. CSCs are highly tumorigenic with an unlimited proliferation potential and capacity to generate malignant tumors. Furthermore, CSCs are also known to resist conventional chemotherapy as well as more contemporary targeted therapies alike. Therefore, given the complexity of CSCs and their clinical relevance, new methods must follow to more effectively study and characterize CSC mechanisms that allow them to proliferate and persist, and to develop drugs and other therapies that can more effectively target these populations. Herein, we present a HCS method to quantify the number and size of colonies in 2D and 3D culture models and to distinguish colonies based on fluorescent markers using an Opera Phenix high-content-screening system. In addition, we present a method to scan at low magnification and rescan at a higher magnification to capture in greater detail colonies or even single cells of interest. These methods can be adapted to numerous applications or other imaging systems to study CSC biology using high-content analysis and for high-throughput drug discovery.

Download full-text PDF

Source
http://dx.doi.org/10.1177/2472555220926921DOI Listing

Publication Analysis

Top Keywords

clonogenic assay
8
advanced high-content-screening
4
high-content-screening applications
4
applications clonogenicity
4
clonogenicity cancer
4
cancer report
4
report 1956
4
1956 puck
4
puck marcus
4
clonogenic
4

Similar Publications

Aim: AHepatocellular carcinoma (HCC) is a malignant neoplasm characterized by a poor prognosis, with its incidence rising globally. Chemokine (C-C motif) ligand 7 (CCL7), a chemokine protein, has been implicated in the progression of various cancers. Nonetheless, the specific role of CCL7 in HCC has yet to be elucidated.

View Article and Find Full Text PDF

Androgen deprivation therapy (ADT) is currently the primary treatment regime for Prostate cancer patients for advanced and local tumors. However, 70 % of the patients develop resistance to ADT due to various underlying mechanisms over the years. Researchers have identified the involvement of Tousled-like kinase 1 (TLK1) as a primary reason for ADT resistance and metastatic tumor development, representing TLK1 as an effective druggable target for prostate cancer.

View Article and Find Full Text PDF

Multiple myeloma (MM), a plasma cell-derived malignant hematological disease, is often treated with bortezomib, a highly effective first-generation proteasome inhibitor. However, resistance to bortezomib is a common occurrence. Profilin 1 (PFN1), a cytoskeleton-related gene known to promote autophagy in MM, induces this resistance to bortezomib, but it is unclear why.

View Article and Find Full Text PDF

Background: Universally, Allium ascalonicum (Shallots) is a well-known flavouring agent in many cuisines. Though, it's been proved for its health benefits due to the presence of alkaloids, flavonoids, terpenoids, phenols and coumarins, its role as an anti-neoplastic agent still requires comprehensive investigation. In our study, we have investigated the presence of potential anti-neoplastic phytocompounds, anti-inflammatory, cytotoxicity and anti-metastatic activity of Shallots against Triple-Negative Breast Cancer cell line, MDA-MB-231.

View Article and Find Full Text PDF

Enhancement of radio-sensitivity by inhibition of Janus kinase signaling with oclacitinib in canine tumor cell lines.

Mol Ther Oncol

March 2025

Laboratory of Veterinary Surgery, Department of Veterinary Clinical Sciences, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan.

A combination of irradiation and oclacitinib, a Janus kinase (JAK) inhibitor used in dogs, could lead to synergistic anticancer effects in canine tumors. However, the anti-tumor effects of oclacitinib remain unclear. This study investigated the radio-sensitizing effect of oclacitinib in canine tumors and determined its underlying mechanisms using osteosarcoma (HMPOS), malignant melanoma (CMeC), and thyroid adenocarcinoma (CTAC) cell lines.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!